The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
Abstract
In Alzheimer's disease, age-related cellular changes such as compromised energy production and increased radical formation are worsened by the presence of AGEs as additional, AD specific stress factors. Intracellular AGEs (most likely derived from methylglyoxal) crosslink cytoskeletal proteins and render them insoluble. These aggregates inhibit cellular functions including transport processes and contribute to neuronal dysfunction and death. Extracellular AGEs, which accumulate in ageing tissue (but most prominently on long-lived protein deposits like the senile plaques) exert chronic oxidative stress on neurons. In addition, they activate glial cells to produce free radicals (superoxide and NO) and neurotoxic cytokines such as TNF-alpha. Drugs, which inhibit the formation of AGEs by specific chemical mechanisms (AGE-inhibitors), including aminoguanidine, carnosine, tenilsetam, OPB-9195 and pyridoxamine, attenuate the development of (AGE-mediated) diabetic complications. Assuming that 'carbonyl stress' contributes significantly to the progression of Alzheimer's disease, AGE-inhibitors might also become interesting novel therapeutic drugs for treatment of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of RAGe by its ligands results in the upregulation of several inflammatory signalling pathways, including, but not limited to, NF-κb, phospho inositide 3-kinase, Janus kinase (JAK)–signal transducer and activator of transcription (STAT) and MAPK signalling pathways, which lead to induction of pro-inflammatory cytokines such as TNF19,91,95,96.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [96]
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Advanced protein glycosylation in diabetes and aging
Brownlee, M. D. (1995) · Annual Review of Medicine · doi:10.1146/annurev.med.46.1.223 · Cited by 1,312
Staging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 5×
“An acute decrease in cellular GSH, as occurs in oxidative stress, leads to decreased in situ activity of glyoxalase I, accumulation of -oxoaldehydes and cytotoxicity ( Abordo et al. 1999 ).”
BackgroundInfluentialLander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Advanced glycation end products contribute to amyloidosis in Alzheimer disease
Vitek, M. P., Bhattacharya, K., Glendening, J. M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., & Cerami, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4766 · Cited by 806
Bush, A. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00073-3 · Cited by 731
Advanced Maillard reaction end products are associated with Alzheimer disease pathology.
Smith, M. A., Taneda, S., Richey, P. L., Miyata, S., Yan, S. D., Stern, D., Sayre, L. M., Monnier, V. M., & Perry, G. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5710 · Cited by 715
Wells‐Knecht, K. J., Zyzak, D. V., Litchfield, J., Thorpe, S. R., & Baynes, J. (1995) · Biochemistry · doi:10.1021/bi00011a027 · Cited by 594
Shinohara, M., Thornalley, P. J., Giardino, I., Beisswenger, P. J., Thorpe, S. R., Onorato, J., & Brownlee, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119885 · Cited by 513
Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease.
McShea, A., Harris, P. L. R., Webster, K. R., Wahl, A. F., & Smith, M. A. (1997) · Europe PMC (PubMed Central) · Cited by 422
Flagged first, then by citations
1 of the 83 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Czech C, Monning U, Tienari PJ, Hartmann T, Masters C, Beyreuther K and Forstl H (1993) Apolipoprotein-e-sigma-4 allele and alzheimers disease. Lancet 342: 1309-1310
- Khalifah RG, Baynes JW and Hudson BG (1999) Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257: 251-258 · DOI
Cited by
Sorted by citations
Items 101–113 of 113
Personalized Management of Selected Neurological Disorders
Ekvall, S. W., Westermarck, T., Havia, M., & Atroshi, F. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92002 · Cited by 3
Song, Y., Du, Y., An, Y., Zheng, J., & Lu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1036315 · Cited by 2
Laser treatment in cosmetic dermatology
Funasaka, Y. (2006) · Nippon Laser Igakkaishi · doi:10.2530/jslsm.27.309 · Cited by 2
Aminoguanidin ve Hastaliklardaki Önemi
Özgüneş, H., & Atasayar, S. (2009) · Turkiye Klinikleri Tip Bilimleri Dergisi · Cited by 1
Hashimoto, Y. (2008) · Institutional Repositories DataBase (IRDB) · Cited by 1
Identification of N?-(carboxymethyl)lysine-positive cells in astroglia-rich primary cultures
Pawlowski, P., & Dringen, R. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0020-z · Cited by 1
The Biology of Aging and Related Nuclear Medicine Studies
Pierson, R. N., & Shreeve, W. W. (2003) · Springer eBooks · doi:10.1007/978-3-642-55539-8_13
Cano, H., Hernández‐Espinosa, D., Miñano, A., del Rey, M. L., Illán, F., Alcaraz, M. S., Pascual, M., Guerrero, J. A., Vicente, V., & Corral, J. (2005) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(05)73344-1
Non-Invasive Method for Detecting Skin Autofluorescence of Advanced Glycation End Products
Liu, Y., Zhang, L., Zhu, L., Wang, Y., Wang, A., & Feng, Y. (2009) · International Conference on Biomedical Engineering and Informatics (BMEI) · doi:10.1109/bmei.2009.5305228
(2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.276
(2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.374
Khongkla, E., Boonsnongcheep, P., Srisaisup, M., & Charuraksa, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.31.762905
Assessment of Protein Glycoxidation in Ventricular Tissues
Li, S., & Ren, J. T. (2007) · Methods in molecular medicine · doi:10.1007/978-1-59745-571-8_21
Metadata
- Authors
- Dukic-Stefanovic, S., Schinzel, R., Riederer, P., & Münch*, G.
- Affiliations
- University of Würzburg (DE)
- Venue
- Biogerontology
- Published
- 2001-03
- Volume
- 2
- Issue
- 1
- Pages
- 19-34
- ISSN
- 1389-5729 (ISSN-L)
- 1573-6768
- OpenAlex
- W17453112
- Cited by
- 113
- References
- 83
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 9 · 2013: 4 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biogerontology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Physiology (medical) › Biochemical effects in animals
- Keywords
- advanced glycation end products, AGE inhibitors, Alzheimer's disease, neuroprotection, anti-dementia drugs, methylglyoxal, carbonyl stress, oxidative stress, amyloid plaques, aminoguanidine, carnosine, pyridoxamine, glial activation, neuronal dysfunction, brain aging
- MeSH terms
- Aging, Alzheimer Disease, Animals, Brain, Dementia, Humans, Signal Transduction, Glycation End Products, Advanced, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
